Category Archives: FDA

AMA Moves to Ban Direct-To-Consumer Pharmaceutical Ads

According to the AMA, direct-to-consumer advertising of pharmaceuticals and medical devices drives up health care costs and should be banned. [More…]

Posted in Advertising, Antidepressant medication, Antipsychotic medication, Bipolar Depression, Bipolar Disorder, Depression, Direct-to-Consumer, Drug marketing, FDA, Health Industry, Mental health, News, Pharmaceutical Industry | Comments Off on AMA Moves to Ban Direct-To-Consumer Pharmaceutical Ads

Development and Regulation of Abuse-Deterrent Opioid Medications – FDA Public Meeting

The FDA is hosting a public meeting on October 30 and 31, 2014 to discuss the development, assessment, and regulation of abuse-deterrent formulations of opioid medications. The meeting will focus on scientific and technical issues related to the development and … Continue reading

Posted in Drugs, FDA, Opioids, Substance abuse | Comments Off on Development and Regulation of Abuse-Deterrent Opioid Medications – FDA Public Meeting